Rebekka Duhen joins the CEDAR institute as a Senior Scientist after 7 years at the EACRI at the Providence Cancer Institute in Portland, OR. There, she studied the role of CD4 and CD8 T cells in tumors and aided in the identification of tumor-reactive T cell subsets. Another focus of her work was on the co-stimulatory molecule OX40 and its role in immunotherapy. At CEDAR, Rebekka will focus on the role and use of immune cells in early cancer detection. Rebekka received her diploma from the Technical University of Dresden, Germany and received her Ph.D from the University of Bern and the Institute for Research in Biomedicine, in Bellinzona, Switzerland, where she studied ways to assess the human T cell repertoire and assisted in the identification of the Th22 skin-homing T cell subset. Following her Ph.D, Rebekka joined the Benaroya Research Institute in Seattle, WA from 2010-2015 to help define the role of pathogenic T cells in EAE. She is very excited to bring her expertise in both human and mouse T cell immunology to CEDAR and to develop new strategies using the immune system and/or its signatures to improve early cancer detection approaches.